Radiotherapy for malignant pleural mesothelioma.

@article{Chapman2006RadiotherapyFM,
  title={Radiotherapy for malignant pleural mesothelioma.},
  author={Erica Chapman and E G Berenstein and Marcelo Garc{\'i}a Dieguez and Zachary Ortiz},
  journal={The Cochrane database of systematic reviews},
  year={2006},
  volume={3},
  pages={
          CD003880
        }
}
BACKGROUND Malignant pleural mesothelioma is a relatively uncommon disease, but the incidence is increasing and is expected to peak in many developed countries in the next two decades. The management of patients with malignant mesothelioma is controversial. Very few patients are suitable for any potentially curative treatment and the effectiveness of radical therapy with surgery, radiotherapy and/or chemotherapy in curing patients or prolonging survival is uncertain. The role of radiotherapy is… Expand
Radical multimodality therapy for malignant pleural mesothelioma.
TLDR
The overall strength of the evidence gathered in this review is low and there is a lack of available evidence to support the use of radical multimodality therapy in routine clinical practice (particularly as one trial suggests greater harm). Expand
Multidisciplinary treatment of malignant pleural mesothelioma.
TLDR
There have been several major advances in the management of patients with MPM, including more accurate staging and patient selection, improvements in surgical techniques and postoperative care, novel chemotherapy regimens with definite activity such as antifolate (pemetrexed or raltitrexed)-platinum combinations, and new radiotherapy techniques such as intensity-modulated radiation therapy. Expand
Radiotherapy in malignant pleural mesothelioma.
TLDR
RT has been used in the management of MPM in three ways: as prophylaxis to reduce the incidence of recurrence and pain at sites of diagnostic or therapeutic instrument insertion, as part of multimodal definitive treatment to improve locoregional control after resection of early-stage disease, and for palliation of symptoms for patients with advanced disease. Expand
Multimodality treatment of malignant pleural mesothelioma
TLDR
Research into the effects of trimodality treatment approaches have found that radical approaches such as EPP and hemithoracic RT post-EPP are less effective than was previously assumed, and more research into multimodality therapy will provide insight into which combination of treatment modalities is most effective. Expand
Management Options for Malignant Pleural Mesothelioma
TLDR
In the future, new multimodality regimens featuring novel targeted therapies directed against molecular targets, such as the vascular endothelial growth factor, hold the greatest promise for improved outcomes in MPM. Expand
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.
TLDR
Palliative radiotherapy produces a response rate in MPM that is equivalent to chemotherapy, and the EORTC prognostic index can be used to select patients who are most likely to benefit from this treatment. Expand
Investigational Approaches for Mesothelioma
TLDR
This review provides an update of the major clinical trials that impact mesothelioma treatment, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesot helioma is moving. Expand
Modern Radiotherapy Techniques in Malignant Pleural Mesothelioma
TLDR
Every patient with MPM should receive RT in the adjuvant setting, and more advanced technology has been shown to result in better target coverage with decreased rates of toxicity. Expand
Can ▼pemetrexed help in malignant mesothelioma?
  • Medicine
  • Drug and therapeutics bulletin
  • 2006
TLDR
Pemetrexed has recently become available for use with cisplatin for the treatment of patients with unresectable malignant pleural mesothelioma who have not previously been treated with chemotherapy. Expand
Role of postoperative radiotherapy in the management of malignant pleural mesothelioma
TLDR
Evidence from this analysis is insufficient on its own to routinely recommend postoperative radiotherapy for surgically resected MPM, however, large-scale prospective clinical trials are warranted to further evaluate this intervention in nonsarcomatoid histology. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
TLDR
Extrapleural pneumonectomy with adjuvant therapy is appropriate treatment for selected patients with malignant mesothelioma selected using a revised staging system. Expand
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
TLDR
Treatment of this disease appeared to fail because of the unresponsiveness of the tumour to existing forms of treatment and the advanced stage of the disease at clinical presentation. Expand
The role of palliative radiotherapy in malignant mesothelioma.
TLDR
Pain control improved in 13/19 patients at 1 month, but 9/12 patients had worsening chest pain at 3 months, and at 5 months pain control had deteriorated in 6/7 patients, and the median duration of survival after RT was 4 months. Expand
Malignant mesothelioma of the pleura
TLDR
Although in the Cox model analyses the survival improvement of patients being treated could be greatly attributed to other cofactors, multimodal treatment showed some prolongation of life expectancy. Expand
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
TLDR
Identification of prognostic factors in patients with malignant pleural mesothelioma based on prospectively collected international data may help to design new clinical trials in pleural Mesot Helioma by selecting more homogenous groups of patients. Expand
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
TLDR
Findings confirm the efficacy and safety of early local radiotherapy in preventing malignant seeding after invasive diagnostic procedures in patients with malignant pleural mesothelioma. Expand
5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
TLDR
This series confirms the reproducibility of the trimodality treatment for MPM, which is associated with prolonged survival for early-stage tumors at the cost of a not prohibitive treatment-related mortality rate. Expand
Chemotherapy in malignant pleural mesothelioma. A review.
  • S. Ong, N. Vogelzang
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
The successful treatment of unresectable pleural mesothelioma awaits the discovery of active drugs, and off-protocol combination therapy cannot be recommended over single-agent therapy, but studies that use combinations of the newer agents should be conducted. Expand
A review of chemotherapy trials for malignant mesothelioma.
TLDR
A review of the literature reveals that small activity against this disease has been shown by the anthracyclines, platinum compounds, and alkylating agents, whereas higher activity has been reported with the antimetabolites. Expand
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
TLDR
The discovery of elevated levels of various markers such as folic acid receptor alpha, cyclooxygenase 2, and multidrug resistance proteins 1 and 2 in mesothelioma tissue have opened up new areas of potential diagnostic and therapeutic importance. Expand
...
1
2
3
4
5
...